Related Experiment Video

Updated: Aug 6, 2026

Spectrophotometric Screening for Potential Inhibitors of Cytosolic Glutathione S-Transferases
14:57

Spectrophotometric Screening for Potential Inhibitors of Cytosolic Glutathione S-Transferases

Published on: October 10, 2020

Microsomal glutathione transferase 1 in anticancer drug resistance

Katarina Johansson1, Karin Ahlen, Rosanna Rinaldi

  • 1Institute of Environmental Medicine, Division of Biochemical Toxicology, Karolinska Institutet SE-171 77 Stockholm, Sweden. katarina.johansson@ki.se

Carcinogenesis
|August 22, 2006
PubMed

Insights

Membrane-bound microsomal glutathione transferase 1 (MGST1) enhances cancer cell survival against chemotherapy drugs. This study demonstrates MGST1

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Cancer Research

Background:

  • Glutathione transferases (GSTs) are implicated in cancer drug resistance.
  • The role of membrane-bound GSTs, like MGST1, in this resistance is not well understood.
  • Upregulation of GSTs in tumors suggests a potential role in chemotherapy efficacy.

Purpose of the Study:

  • To investigate the involvement of membrane-bound microsomal glutathione transferase 1 (MGST1) in cellular resistance to anticancer drugs.
  • To elucidate the protective mechanisms of MGST1 against cytostatic agents.

Main Methods:

  • Developed a stable MCF7 cell line overexpressing MGST1.
  • Assessed cellular resistance using MTT assays (acute toxicity) and colony-forming efficiency tests (long-term cytotoxicity).
  • Evaluated protection against various cytostatic drugs, including known and non-substrate drugs.

Main Results:

  • MCF7 cells overexpressing MGST1 exhibited significant protection against chlorambucil, melphalan, and cisplatin.
  • Protection was observed in both acute and long-term cytotoxicity assays.
  • MGST1-mediated protection occurred independently of multidrug transporter overexpression.

Conclusions:

  • Membrane-bound microsomal glutathione transferase 1 (MGST1) confers cellular resistance to multiple anticancer drugs.
  • MGST1 likely protects cells through direct drug detoxification and mitigation of oxidative stress.
  • These findings highlight MGST1 as a potential therapeutic target in cancer treatment.

More Related Videos

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

Related Concept Videos

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation01:22

Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation

Glutathione, a tripeptide made up of glutamate, cysteine, and glycine, is a critical player in the detoxification of drugs and xenobiotics via a process known as glutathione conjugation or mercapturic acid formation. This phase II biotransformation reaction involves the covalent binding of glutathione to a drug or its metabolite, enhancing the compound's water solubility and enabling its excretion.
Several distinctive characteristics distinguish glutathione conjugation from other phase II...
Carrier-Mediated Transport01:06

Carrier-Mediated Transport

Carrier-mediated transport is a pivotal process in drug absorption, particularly for lipid-insoluble drugs, and encompasses facilitated diffusion and active transport. Facilitated diffusion allows drugs to move along their concentration gradient without energy expenditure, while active transport utilizes ATP to drive drug movement against this gradient.
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...